# Prognostic Value of Cerebrospinal Fluid Immunoglobulin Free Light Chains in Patients With Multiple Sclerosis

> **NCT05072691** · — · RECRUITING · sponsor: **Francis Corazza** · enrollment: 100 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DIAGNOSTIC_TEST:** CSF immunoglobulin (Ig) free light chains (FLC) dosage

## Key facts

- **NCT ID:** NCT05072691
- **Lead sponsor:** Francis Corazza
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2020-07-14
- **Primary completion:** 2030-01-01
- **Final completion:** 2030-01-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05072691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05072691, "Prognostic Value of Cerebrospinal Fluid Immunoglobulin Free Light Chains in Patients With Multiple Sclerosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05072691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*